جامعة المعرفة
المصدر المعتمد للمعلومات البحثية والمخرجات هو قاعدة بيانات سكوبس (Elsevier Scopus) مع تدقيق بيانات الباحثين من عمادة البحث العلمي.
WA

Waqar Ali

بانتظار توثيق الانتساب2024–2026
46وثائق Scopus
399استشهاداً
11مؤشر h
18منها بانتماء الجامعة
إجمالي Scopus (كل الجهات)ملف الباحث في Scopus ↗آخر تحديث: 2026-11-09

كل وثائق Scopus للباحث

46
مراجعةمفتوح (مستودع)2026

Early Versus Late Initiation of High-Efficacy Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis: A Systematic Review and Meta-Analysis

Annals of Middle Eastern Medicine

Background: Relapsing-remitting multiple sclerosis is a chronic immune-mediated disorder of the central nervous system associated with recurrent inflammatory activity and long-term disability accumulation. Although escalation therapy has traditionally been used, early initiation of high-efficacy disease-modifying therapies may provide stronger inflammatory control and improve long-term outcomes. Objective: This systematic review and meta-analysis aimed to compare early initiation of high-efficacy disease-modifying therapies with escalation or delayed treatment strategies in adults with relapsing-remitting multiple sclerosis. Methods: PubMed, Scopus, and Web of Science were systematically searched. Eligible studies included adults with relapsing-remitting multiple sclerosis treated with either early high-efficacy disease-modifying therapies or escalation/delayed strategies. Outcomes included annualized relapse rate, Expanded Disability Status Scale change, and delta-Expanded Disability Status Scale. Study quality was assessed using the Newcastle-Ottawa Scale, and pooled analyses were performed using random-effects models. Results: Ten observational cohort studies were included. Early initiation of high-efficacy treatment was associated with lower annualized relapse rate than escalation therapy. Disability findings remained uncertain. The pooled EDSS-change analysis was not statistically significant and showed considerable heterogeneity. Only one eligible study reported an adjusted delta-EDSS comparison; therefore, this outcome was reported narratively and was not meta-analyzed. Nonrandom treatment allocation and potential confounding by indication limit causal interpretation. Conclusion: Early initiation of high-efficacy disease-modifying therapy was associated with lower relapse activity in observational RRMS cohorts. The available disability evidence does not establish a causal advantage of either treatment strategy and requires cautious interpretation.

relapsing-remitting multiple sclerosisdisease-modifying therapyearly treatment initiationtreatment delay
مقالوصول مغلق2024

PREVALENCE OF HYPERURICEMIA AND GOUT AND THEIR RELATIONSHIP TO CERTAIN RISK FACTORS: A SYSTEMATIC REVIEW

Indian Journal Of Applied Research · 1-5

Background/ objectives: The frequency of related comorbidities, all-cause mortality, and societal costs are all on the rise, and so is the burden of gout and hyperuricemia globally. This systematic review aims to investigate the recently published literature on the prevalence and risk factors of gout and hyperuricemia. PubMed, Web of S Methods: cience, Science Direct, and Cochrane Library were systematically searched to include the relevant literature. Rayyan QRCI was used throughout this systematic approach. Results: Our results included eleven studies with a total of 204,759,079 patients diagnosed with gout and/ or hyperuricemia. The reported total prevalence of hyperuricemia was 40,169,245 (19.6%), and the prevalence of gout was 6,192,105 (3.02%). The included studies recorded a rising incidence of gout and hyperuricemia. Gout is thus an increasing problem over the world, and to addr Conclusion: ess and improve widespread poor care, international cooperation efforts are needed. Hyperuricemia and gout affected males more than females. Older age, obesity, male gender, less activity, a diet heavy in purines, and lower educational levels all had an impact on blood UA concentration. These are high-risk populations that need to have their UA levels regularly checked.

hyperuricemiagoutprevalencerisk factors